The subject of the above mentioned scientific research is innovative approach to spinal anaesthesia, i.e. creation of new combined anaesthetic with its further application in surgery, which, in scientists’ estimation, will make possible to reduce post-surgicalneuropatic pain. The project will be started with pre-clinical research, and, within the space of nearly two years, clinical research will be carried out.

Vitālijs Skrīvelis, Director of Grindeks Active Pharmaceutical Ingredients Business Unit, laying special emphasis on the global level of high quality and marketability of active pharmaceutical ingredients produced by Grindeks says: ”The contract on oxytocin supply concluded between Grindeks and respectable USA Research Centre, has resulted from purposeful activities ensuring products quality and preparing documentation, whereupon the product we are manufacturing had been admitted the most qualitative to be chosen for research project to implement. Currently, Grindeks is highly demanded high-quality active pharmaceutical ingredients producer and supplier to more than 30 countries, including USA which is one of the most particular about quality from every country around the world”.

James C. Eisenach, III Professor of Anaesthesiology, and Director of the Center for the Study of Pharmacologic Plasticity in the Presence of Pain of Wake Forest University School of Medicine stresses: “Our centre chose Grindeks because of their history of producing high quality oxytocin that meets rigorous standards in Europe and the USA”.

Wake Forest University School of Medicine is a leading research center in the U.S. in the study of pain and analgesia, and internationally recognized in the study of drug administration by the spinal route in the treatment of chronic pain. It has been supported by the National Institutes of Health in the USA for 20 years for preclinical, clinical introduction, and clinical trials of analgesic drugs administered by the spinal route.

Grindeks is the leading pharmaceutical company in the Baltic States. Its main fields of action are research, development and manufacturing of brand products, generics and active pharmaceutical ingredients (API).

Grindeks is carrying out successfully API promotion both on existing and new markets, whereupon API exports had reached 5.4 million euro in 2007,which is by 1million euro or 22% more than in 2006. Oxytocin is one of the most demanded Grindeks API. Exporting it, Grindeks has gained 35% of the world market. Market position strengthening and footholds gaining in new markets are being advantaged by international certificates proving the quality of oxytocin, such as Certificate on production conformity with Good Manufacturing Practice, Certificate of Suitability which is facilitating registration of the product in any and all countries where Europe pharmacopoeia is applicable, as well as Food and Drug Administration conclusion affirming conformity with USA quality standards.

Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of Grindeks’ products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein.

Grindeks concern consists of four subsidiary companies in Latvia, Estonia and Russia as well as ten representative offices. Products of the company are exported to more than 40 countries. Main markets are the Baltic States, Russia and CIS countries, Japan, USA. Grindeks shares are listed in the Official List of Riga Stock Exchange.

 

Laila Klaviņa
Head of the Communications Department
JSC Grindeks
Phones: +371 67083370, +371 29256012
E-mail: laila.klavina@grindeks.lv